Gelesis announced today that it partnered with China Medical Systems for the commercialization of the Plenity weight loss pill in China.
Under the terms of the deal, CMS will provide $35 million upfront via licensing fees and equity investment, plus there remains the potential for an additional $388 million in future milestone payments, as well as royalties.
“There is a huge need but limited options for patients seeking treatment for overweight and obesity, so we are excited to be able to offer Plenity to patients in China in the future,” CMS GM of global investment & operations Huaizheng Peng said in a news release. “Its highly desirable efficacy and safety profile make it an ideal choice for many patients looking for early intervention treatment for overweight.”
Plenity, based on Gelesis’ proprietary hydrogel platform, is an orally-administered, non-systemic and non-stimulant aid for weight management, taken in the form of c…